Home / Business and Economy / AbbVie Buys Apogee Therapeutics for $10.9B
AbbVie Buys Apogee Therapeutics for $10.9B
22 Jun
Summary
- AbbVie is acquiring Apogee Therapeutics for $10.9 billion in cash.
- The acquisition aims to strengthen AbbVie's next-generation immunology pipeline.
- Apogee's lead drug candidate, zumilokibart, targets inflammatory diseases.
AbbVie announced on Monday, June 22, 2026, its intention to acquire Apogee Therapeutics for a substantial $10.9 billion in cash. This acquisition is designed to significantly enhance AbbVie's pipeline of next-generation immunology treatments.
The U.S. drugmaker's offer of $135.11 per Apogee share represents a considerable premium. The deal grants AbbVie access to Apogee's key drug candidate, zumilokibart. This experimental treatment is being developed for a variety of inflammatory diseases, including moderate-to-severe atopic dermatitis and asthma.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
